These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 21292775)

  • 21. International uniform response criteria for multiple myeloma.
    Durie BG; Harousseau JL; Miguel JS; Bladé J; Barlogie B; Anderson K; Gertz M; Dimopoulos M; Westin J; Sonneveld P; Ludwig H; Gahrton G; Beksac M; Crowley J; Belch A; Boccadaro M; Cavo M; Turesson I; Joshua D; Vesole D; Kyle R; Alexanian R; Tricot G; Attal M; Merlini G; Powles R; Richardson P; Shimizu K; Tosi P; Morgan G; Rajkumar SV;
    Leukemia; 2006 Sep; 20(9):1467-73. PubMed ID: 16855634
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation.
    Durie BG; Kyle RA; Belch A; Bensinger W; Blade J; Boccadoro M; Child JA; Comenzo R; Djulbegovic B; Fantl D; Gahrton G; Harousseau JL; Hungria V; Joshua D; Ludwig H; Mehta J; Morales AR; Morgan G; Nouel A; Oken M; Powles R; Roodman D; San Miguel J; Shimizu K; Singhal S; Sirohi B; Sonneveld P; Tricot G; Van Ness B;
    Hematol J; 2003; 4(6):379-98. PubMed ID: 14671610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Response Assessment in Myeloma: Practical Manual on Consistent Reporting in an Era of Dramatic Therapeutic Advances.
    Garderet L; D'Souza A; Jacobs P; van Biezen A; Schönland S; Kroeger N; Morris C; Hari P
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1193-1202. PubMed ID: 28285082
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma.
    Martino M; Lemoli RM; Girmenia C; Castagna L; Bruno B; Cavallo F; Offidani M; Scortechini I; Montanari M; Milone G; Postacchini L; Olivieri A
    Bone Marrow Transplant; 2016 Aug; 51(8):1032-40. PubMed ID: 27042841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review.
    Mohyuddin GR; Koehn K; Abdallah AO; W Sborov D; Rajkumar SV; Kumar S; McClune B
    Am J Hematol; 2021 Jun; 96(6):690-697. PubMed ID: 33735453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. What did we learn in 2010 from the phase III trials? Is maintenance therapy the new standard for myeloma?
    Giralt S; Stadtmauer E; McCarthy P
    Biol Blood Marrow Transplant; 2011 Jan; 17(1 Suppl):S30-2. PubMed ID: 21195307
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation and appraisal of randomized controlled trials in myeloma.
    Djulbegovic B; Adams JR; Lyman GH; Lacevic M; Hozo I; Greenwich M; Bennett CL
    Ann Oncol; 2001 Nov; 12(11):1611-7. PubMed ID: 11822763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. International staging system and metaphase cytogenetic abnormalities in the era of gene expression profiling data in multiple myeloma treated with total therapy 2 and 3 protocols.
    Waheed S; Shaughnessy JD; van Rhee F; Alsayed Y; Nair B; Anaissie E; Szymonifka J; Hoering A; Crowley J; Barlogie B
    Cancer; 2011 Mar; 117(5):1001-9. PubMed ID: 20945320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.
    Palumbo A; Sezer O; Kyle R; Miguel JS; Orlowski RZ; Moreau P; Niesvizky R; Morgan G; Comenzo R; Sonneveld P; Kumar S; Hajek R; Giralt S; Bringhen S; Anderson KC; Richardson PG; Cavo M; Davies F; Bladé J; Einsele H; Dimopoulos MA; Spencer A; Dispenzieri A; Reiman T; Shimizu K; Lee JH; Attal M; Boccadoro M; Mateos M; Chen W; Ludwig H; Joshua D; Chim J; Hungria V; Turesson I; Durie BG; Lonial S;
    Leukemia; 2009 Oct; 23(10):1716-30. PubMed ID: 19494840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
    Moreau P; Sonneveld P; Boccadoro M; Cook G; Mateos MV; Nahi H; Goldschmidt H; Dimopoulos MA; Lucio P; Bladé J; Delforge M; Hajek R; Ludwig H; Facon T; Miguel JFS; Einsele H
    Haematologica; 2019 Dec; 104(12):2358-2360. PubMed ID: 31439675
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
    Raje NS; Anaissie E; Kumar SK; Lonial S; Martin T; Gertz MA; Krishnan A; Hari P; Ludwig H; O'Donnell E; Yee A; Kaufman JL; Cohen AD; Garderet L; Wechalekar AF; Terpos E; Khatry N; Niesvizky R; Yi Q; Joshua DE; Saikia T; Leung N; Engelhardt M; Mothy M; Branagan A; Chari A; Reiman AJ; Lipe B; Richter J; Rajkumar SV; Miguel JS; Anderson KC; Stadtmauer EA; Prabhala RH; McCarthy PL; Munshi NC
    Lancet Haematol; 2022 Feb; 9(2):e143-e161. PubMed ID: 35114152
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
    Sonneveld P; Avet-Loiseau H; Lonial S; Usmani S; Siegel D; Anderson KC; Chng WJ; Moreau P; Attal M; Kyle RA; Caers J; Hillengass J; San Miguel J; van de Donk NW; Einsele H; Bladé J; Durie BG; Goldschmidt H; Mateos MV; Palumbo A; Orlowski R
    Blood; 2016 Jun; 127(24):2955-62. PubMed ID: 27002115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The next generation of therapy for multiple myeloma: a review of ongoing clinical trials utilizing ClinicalTrials.gov.
    Barth P; Vale C; Chambers AB; Reagan JL
    Future Oncol; 2018 Aug; 14(19):1965-1976. PubMed ID: 30019947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases.
    Chow E; Wu JS; Hoskin P; Coia LR; Bentzen SM; Blitzer PH
    Radiother Oncol; 2002 Sep; 64(3):275-80. PubMed ID: 12242115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group.
    Tsang RW; Campbell BA; Goda JS; Kelsey CR; Kirova YM; Parikh RR; Ng AK; Ricardi U; Suh CO; Mauch PM; Specht L; Yahalom J
    Int J Radiat Oncol Biol Phys; 2018 Jul; 101(4):794-808. PubMed ID: 29976492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when.
    Caers J; Garderet L; Kortüm KM; O'Dwyer ME; van de Donk NWCJ; Binder M; Dold SM; Gay F; Corre J; Beguin Y; Ludwig H; Larocca A; Driessen C; Dimopoulos MA; Boccadoro M; Gramatzki M; Zweegman S; Einsele H; Cavo M; Goldschmidt H; Sonneveld P; Delforge M; Auner HW; Terpos E; Engelhardt M
    Haematologica; 2018 Nov; 103(11):1772-1784. PubMed ID: 30171031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The majority of newly diagnosed myeloma patients do not fulfill the inclusion criteria in clinical phase III trials.
    Klausen TW; Gregersen H; Abildgaard N; Andersen NF; Frølund UC; Gimsing P; Helleberg C; Vangsted AJ
    Leukemia; 2019 Feb; 33(2):546-549. PubMed ID: 30267010
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
    Moreau P; Kumar SK; San Miguel J; Davies F; Zamagni E; Bahlis N; Ludwig H; Mikhael J; Terpos E; Schjesvold F; Martin T; Yong K; Durie BGM; Facon T; Jurczyszyn A; Sidana S; Raje N; van de Donk N; Lonial S; Cavo M; Kristinsson SY; Lentzsch S; Hajek R; Anderson KC; João C; Einsele H; Sonneveld P; Engelhardt M; Fonseca R; Vangsted A; Weisel K; Baz R; Hungria V; Berdeja JG; Leal da Costa F; Maiolino A; Waage A; Vesole DH; Ocio EM; Quach H; Driessen C; Bladé J; Leleu X; Riva E; Bergsagel PL; Hou J; Chng WJ; Mellqvist UH; Dytfeld D; Harousseau JL; Goldschmidt H; Laubach J; Munshi NC; Gay F; Beksac M; Costa LJ; Kaiser M; Hari P; Boccadoro M; Usmani SZ; Zweegman S; Holstein S; Sezer O; Harrison S; Nahi H; Cook G; Mateos MV; Rajkumar SV; Dimopoulos MA; Richardson PG
    Lancet Oncol; 2021 Mar; 22(3):e105-e118. PubMed ID: 33662288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.